发布求助
文献互助 智能选刊 最新文献

Reviews in gastroenterological disorders最新文献

筛选
英文 中文
Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. 克罗恩病的序贯治疗:优化传统和生物策略。
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Shani Desilva, Gil Kaplan, Remo Panaccione
{"title":"Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.","authors":"Shani Desilva,&nbsp;Gil Kaplan,&nbsp;Remo Panaccione","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The current guidelines for the management of Crohn's disease (CD) suggest a stepwise approach to treatment according to the severity of clinical presentation. The use of tumor necrosis factor (TNF) antagonists are currently reserved for patients who do not respond to conventional nonbiological therapies such as corticosteroids and immunosuppressants. However, as TNF-alpha antagonists have the potential to produce mucosal healing in CD, earlier more aggressive treatment with biologics has been advocated. Anti-TNF therapy may be most beneficial in the early stages of inflammatory disease, before patients develop complications such as fibrostenotic or penetrating disease. Thus, the use of the more aggressive \"top-down\" strategy involving early introduction of biologics has been explored. Emerging data suggest that earlier use of biological therapy is associated with improved clinical outcomes and potential disease-modifying effects. Future studies are warranted and will likely lead to the expanded use of such agents in the treatment of CD.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 2","pages":"109-16"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27547433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infectious disease. Vancomycin should be the drug of choice for severe Clostridium difficile-associated diarrhea. 传染病。万古霉素应作为治疗严重艰难梭菌相关性腹泻的首选药物。
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Edward C Oldfield
{"title":"Infectious disease. Vancomycin should be the drug of choice for severe Clostridium difficile-associated diarrhea.","authors":"Edward C Oldfield","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 4","pages":"270-1"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27920998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. 在炎症性肠病中同时使用免疫抑制剂和生物制剂的风险和益处。
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Shamita B Shah, Stephen B Hanauer
{"title":"Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.","authors":"Shamita B Shah,&nbsp;Stephen B Hanauer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>With the introduction of biologic therapies for inflammatory bowel disease, significant questions have arisen regarding their best optimization. Although initial recommendations were to combine immunosuppressives with biologics to reduce immunogenicity, trials with 3 different anti-tumor necrosis factor agents (infliximab, adalimumab, and certolizumab) and a humanized monoclonal antibody that targets alpha-4 integrins (natalizumab) have failed to demonstrate the clinical superiority of combination therapy when high-dose induction and scheduled maintenance therapy was prescribed for up to 1 year. However, immunosuppressive agents should be considered with episodic biologic therapy to decrease immunogenicity and secondary loss of response. The issue of whether induction with biologics and maintenance therapy with immunosuppressives as monotherapy is as safe and effective as induction and maintenance with biologics alone still remains to be addressed. Further, with the use of concomitant immunosuppressives and biologics, evolving data raise concerns for an increase in adverse events, including opportunistic infections, neurological disorders, and cancer. Specific therapeutic decisions need to be individualized and the clinician must help the patient weigh quality-of-life issues with readiness to assume possible risks.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 3","pages":"159-68"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37435139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver disease. The influence of SOCS3 expression on the treatment response of HCV-related chronic hepatitis patients. 肝脏疾病。SOCS3表达对丙型肝炎相关慢性肝炎患者治疗反应的影响
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Ashaur Azhar, Ira M Jacobson
{"title":"Liver disease. The influence of SOCS3 expression on the treatment response of HCV-related chronic hepatitis patients.","authors":"Ashaur Azhar,&nbsp;Ira M Jacobson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 3","pages":"218-21"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37435145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infectious disease. Endocarditis prophylaxis: new guideline, much less antibiotic prophylaxis. 传染病。心内膜炎预防:新指南，更少抗生素预防。
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Edward C Oldfield
{"title":"Infectious disease. Endocarditis prophylaxis: new guideline, much less antibiotic prophylaxis.","authors":"Edward C Oldfield","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 1","pages":"73-4"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27439454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infectious disease. The nose knows. 传染病。鼻子知道。
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Edward C Oldfield
{"title":"Infectious disease. The nose knows.","authors":"Edward C Oldfield","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 1","pages":"74-5"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27450578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New developments in the treatment of Helicobacter pylori: is sequential therapy the answer? 幽门螺杆菌治疗的新进展:序贯治疗是答案吗?
Reviews in gastroenterological disorders Pub Date : 2008-01-01
Nimish Vakil
{"title":"New developments in the treatment of Helicobacter pylori: is sequential therapy the answer?","authors":"Nimish Vakil","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"8 3","pages":"217-8"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37435144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refining the role of TNF antagonists for Crohn's disease. Introduction. 细化肿瘤坏死因子拮抗剂在克罗恩病中的作用。介绍。
Reviews in gastroenterological disorders Pub Date : 2007-01-01
Stephen B Hanauer, William J Sandborn
{"title":"Refining the role of TNF antagonists for Crohn's disease. Introduction.","authors":"Stephen B Hanauer,&nbsp;William J Sandborn","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"7 Suppl 1 ","pages":"S1-2"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26231983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how? 克罗恩病的临床观点血清学和预后生物标志物:谁、何时、如何?
Reviews in gastroenterological disorders Pub Date : 2007-01-01
Marla C Dubinsky
{"title":"Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?","authors":"Marla C Dubinsky","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The introduction of anti-tumor necrosis factor-a therapies has significantly expanded the armamentarium for patients with inflammatory bowel disease (IBD). Clinical experience has shown that not all patients respond to therapies in this class, which emphasizes the hypothesis that there are different pathways involved in the inflammatory cascade characteristic of the spectrum of IBD phenotypes. The broadening of therapeutics with different mechanisms of action and targets is important for patients with IBD. Based on evidence gathered in recent studies, the key to success with these therapies may lie in targeting the right patients based on knowledge of their underlying genetic defects and resultant immune reactivity. Determining the factors that can predict the progression from uncomplicated to complicated disease states may stratify patients into at-risk populations and have an impact on their ultimate therapeutic management.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"7 Suppl 2 ","pages":"S3-7"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26630690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New guidelines for Helicobacter pylori: applying them to your practice. 幽门螺杆菌的新指南:将其应用于您的实践。
Reviews in gastroenterological disorders Pub Date : 2007-01-01
Vakil Nimish
{"title":"New guidelines for Helicobacter pylori: applying them to your practice.","authors":"Vakil Nimish","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The most recent European Helicobacter Study Group consensus recommendations are a state-of-the-art evaluation of the literature on Helicobacter pylori. The traditional indications for H. pylori eradication remain the major indications for eradication therapy in 2007. A role for H. pylori infection has been demonstrated in disease states that were not traditionally thought to be related to H. pylori infection, namely iron deficiency anemia unexplained by other causes, and idiopathic thrombocytopenic purpura. Office-based H. pylori tests are no longer recommended by the consensus group because of their poor sensitivity and specificity in clinical practice. The treatment of H. pylori infection has not changed significantly in the last decade, though promising alternatives are being studied. At present the treatment regimen recommended for world-wide use is triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Culture and antimicrobial sensitivity testing are recommended in areas where resistance rates to clarithromycin are high.</p>","PeriodicalId":21173,"journal":{"name":"Reviews in gastroenterological disorders","volume":"7 3","pages":"111-4"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27041497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信